OKYO Pharma's Gabriele Cerrone Acquires 24,551 Shares, Total Holding at 10,516,297.

OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company, has announced that Panetta Partners Limited, an entity controlled by Gabriele Cerrone, has acquired 24,551 shares of the company's ordinary shares on NASDAQ, bringing Cerrone's total holding to 10,516,297 shares. The company is developing urcosimod to treat neuropathic corneal pain, an ocular condition with no FDA-approved therapy. Urcosimod works by activating the ChemR23 receptor, which is found on immune cells, neurons, and glial cells in the eye and dorsal root ganglion.